VENTURA COUNTY HEALTH CARE AGENCY

| Drug Class and Medication | Selection and Procurement | Storage | Ordering Verifying and Transcribing | Preparing or Compounding | Administration | Monitoring |
|--|---|---|--|---|--|--|
| Anti-thrombotic agents (anti • Anticoagulants | icoagulants, DOAC, facto | or Xa inhibitors, direct t | hrombin inhibitors, and | thrombolytics) | | |
| warfarin (Coumadin) | Purchased in the following unit dosed strengths to enable intact tablet selection: 1mg, 2 mg, 2.5 mg,5mg | Stocked in automated dispensing cabinets (ADCs) and in pharmacy. | Licensed Independent Practioner (LIP) to use approved PowerPlan to ensure proper labs and monitoring are ordered and must document indication on the order. A baseline INR must be obtained prior to initiation. Pharmacy to ensure that intact tablets are selected at order verification and dispensed. Refer to policy 100.087 and the warfarin protocol. | Unit dose strengths are supplied in designated ADCs. | Warfarin is administered daily at 1400. Refer to policy 100.205 for handling, preparation, and administration guidelines. | INR monitoring will continue daily until goal levels are achieved and then INR levels may be obtained at least twice a week. Monitor for signs and symptoms of bleeding. Refer to Clinical Practice Guideline (CPG) 55 for anticoagulant specific reversal |
| low molecular weight heparin (LMWH, enoxaparin, Lovenox) | Purchased by pharmacy in standard, single dose pre-filled syringes (PFS): 30 mg,40 mg, 60 mg, 80 mg, 100 mg, 120 mg, 150 mg syringes | Pre-filled syringes are stored in pharmacy and in the ADCs with careful consideration to avoid Look-alike/ Sound-Alike (LASA) confusion whenever possible. | LIP to use approved PowerPlans & must document indication on the order Baseline SCr and PLT are required. Doses must be adjusted for indication, weight/BMI, and renal insufficiency per protocol. Please refer to policy 100.087 and the enoxaparin protocol | Pharmacy dispenses pre- filled syringes for adults. For pediatric and neonatal populations, pharmacy compounds the exact dose in syringes. | Enoxaparin is administered at 0900 and/or 2100. | Monitor platelets, Hgb, Hct and SCr routinely. Adjust dose for renal impairment. Monitor patient for bleeding. Enoxaparin is contraindicated in HIT. See CPG.56 for anticoagulant specific reversal |



| Drug Class and Medication | Selection and Procurement | Storage | Ordering Verifying and Transcribing | Preparing or Compounding | Administration | Monitoring |
|--|--|---|--|---|--|--|
| unfractionated heparin, IV and subcutaneous | Purchased by pharmacy in premixed solutions and in 5,000 units/mL syringes. | Stored in ADCs and in pharmacy away from products and look- alike vials that may be mistaken for heparin. Maximum Concentration available is 5,000 units/mL. | LIP to use approved PowerPlans and must document indication on the order 'Units' must be written out. The use of "U" for units is prohibited. Current patient's weight must be available prior to initiating heparin. See Policy 100.087 and heparin drip protocol | Standard concentration of heparin infusion used in adults of 25,000 units/500 mL (50 units/mL). Only one concentration permitted for treatment and prophylaxis. Heparinized saline (2 units/mL) solution is available for arterial lines in select units A 5,000 units/500 mL solution is available for Interventional Radiology (IR) thrombolysis cases only. | Heparin infusions require an independent double check (IDC) and documentation with a 2 nd licensed healthcare professional (HCP) for bolus, start of infusion, rate changes, and bag changes All heparin titrations must be documented in the EHR. Heparin is infused with a programmable pump with a guardrail safety feature. | Refer to heparin protocol for daily labs, timing of anti- Xa lab draws and rate related titrations. Monitor for bleeding, patient's CMP, CBC and Coags, watch for signs and symptoms of HIT (heparin induced thrombocytopenia) with decreased platelets. See CPG.56 for anticoagulant specific reversal. |
| heparin flushes for neonatal and pediatric patients and dialysis heparin lock | Purchased by pharmacy: Preservative free 10 units/mL 5 mL PFS 100 units/mL 5 mL PFS Dialysis 1,000 units/mL single dose vials (SDV) Compounded by pharmacy: 100 units/ 100mL of 0.45% NaCl | Stored in select ADCs and in pharmacy. Stored separately to avoid LASA storage issues. | A standardized and approved Pediatric CVC Line care and flushing order is used when ordering flushes that require heparin. The 10 unit/ mL heparin flushes are labeled as HIGH ALERT prior to dispensing. Nephrologists to use approved power plan. | Standard Heparin flushes are approved for neonatal and pediatric use and are available in premixed, prefilled syringes ready for use by the manufacturer. | All medications administered within the Neonatal and Pediatrics Units should be double checked by two HCP, prior to administration. | See unfractionated heparin above for monitoring. All lines flushed with heparin will be monitored for patency and signs of bleeding. Heparin flushes are contra- indicated in patients with HIT. |

VENTURA COUNTY HEALTH CARE AGENCY

| Drug Class and Medication | Selection and Procurement | Storage | Ordering Verifying and Transcribing | Preparing or Compounding | Administration | Monitoring | | | |
|--|--|---|--|--|--|--|--|--|--|
| Direct oral anticoagulants (DOAC) and factor Xa inhibitors | | | | | | | | | |
| <u>Direct thrombin</u> <u>inhibitor</u> dabigatran (Pradaxa) | Purchased by pharmacy and available in the following strengths: dabigatran 75 mg, 150 mg tabs | Stocked in the ADCs in the appropriate units. | LIPs must document the indication on order. Pharmacist to verify indication for use and ensure the order is appropriate for indication, age, and renal function. Refer to policy 100.087 and DOAC CPG | | | Refer to CPG.56 for anticoagulant specific reversal. | | | |
| <u>Direct factor Xa inhibitor</u> apixaban (Eliquis) | apixaban 2.5mg, 5mg tabs | | | | | | | | |
| rivaroxaban (Xarelto) | rivaroxaban 2.5 mg, 10 mg, 15 mg and 20 mg tabs. | | | | | | | | |
| fondaparinux (Arixtra) Restricted for use in HIT | fondaparinux in 2.5 mg, 5 mg, 7.5 mg and 10 mg syringes. | PFS are stored in pharmacy. | | Pharmacy dispenses pre-filled syringes for adults. For pediatric and neonatal populations, pharmacy compounds the exact dose in syringes. | Fondaparinux is administered at 0900. | | | | |



High Alert – High Risk Medications 2020-2022

| Drug Class and Medication | Selection and Procurement | Storage | Ordering Verifying and Transcribing | Preparing or Compounding | Administration | Monitoring |
|--|---|--|--|--|--|---|
| Direct thrombin inhibitor | rs | | | | | |
| argatroban | Purchased by pharmacy in single dose vials. | Stored in the pharmacy only with careful consideration to avoid LASA confusion whenever possible. | LIP to use approved PowerPlans to ensure dosing, labs, and monitoring are ordered and must document indication on the order. Pharmacist to assess that inclusion and exclusion criteria are met prior to verifying orders. See policy 100.087 and argatroban protocol | Argatroban is compounded by pharmacy in a standard adult 1 mg/mL concentration (250 mg/250 mL). | Argatroban requires an IDC and MAR documentation on with second licensed HCP for start of infusion, rate changes, and bag changes. Use programmable pumps with guardrail safety feature. | Monitor PTT, CBC, CMP, Coag and weight routinely. See argatroban protocol. Initial dose adjustments required in patients with hepatic impairment or is critically ill. See CPG.56 for anticoagulant specific reversal |
| • Thromboylytics alteplase* *alteplase 2mg or (CathFlo®) is NOT High Alert | Purchased and compounded by pharmacy: 50 mg, 10 mg SDV For IR directed Catheter Directed Thrombolysis (CDT): 10 mg/250 mL NS 10 mg/1000 mL NS | Alteplase stored in pharmacy, stroke kit, and select ADCs | Requires a current patient weight in kg. For Stroke: Prescriber to dose in mg as a total dose, using the approved PowerPlan. Inclusion/Exclusion criteria to be reviewed prior to ordering. Refer to policy 100.232 Code Stroke – Intravenous for t-PA (Alteplase) Administration For CDT, prescriber to order alteplase using the approved PowerPlan. | The vials should NOT be shaken or agitated during preparation. Pharmacy to compound bolus syringe and remaining dose of alteplase for ED and ICU at VCMC. SPH ED to prepare doses for emergent need. See policy. | Requires an IDC and documentation with 2 nd licensed HCP for bolus, infusion dose, and start of infusion, plus visualization of drug and syringe Alteplase must be administered using a programmable pump with guardrail safety feature. | Per clinical practice guidelines and Stroke Protocols |



| Drug Class and Medication | Selection and Procurement | Storage | Ordering Verifying and Transcribing | Preparing or Compounding | Administration | Monitoring |
|--|--|---|---|---|---|--|
| Antidiuretic Hormone | | | | | | |
| desmopressin (DDAVP) subcut and IV infusion | Purchased by pharmacy in 4 mcg/mL SDV | Stored in the pharmacy department under refrigeration. | Orders for subcut or IV desmopressin will only be accepted in "mcg" doses. Pharmacist verifying subcut DDAVP orders shall ensure all doses are dispensed and labeled dose in "—mcg =mLs". Pediatric population: Verify dose for age in mcgs, weight in Kg and diagnosis. | Pediatric population: All DDAVP subcut orders will be drawn up and labeled by pharmacy using a 1 mL syringe. Adult population: All doses will be drawn up by nursing using an appropriate syringe. | IV infusions can be administered over 15 to 30 minutes. | Monitor BP and HR during infusions. Also monitor sodium levels, for possible fluid overload, monitor Intake and Output and notify provider for decreased renal function. DDAVP is contraindicated for CrCl of <50 mL/min. |
| Antifungals | | | | | | |
| amphotericin B and amphotericin B Liposomal (AmBisome) | Two products purchased only: conventional Amphotericin B in a 50 mg vial for reconstitution and is restricted to NAB (Neomycin/ amphotericin/ bacitracin) solutions only. AmBisome (Amphotericin B Liposomal) in a 50mg vial for reconstitution. | Products are stored separately within the pharmacy to avoid LASA mix-ups. Amphotericin B is stored in the pharmacy department under refrigeration. AmBisome is stored at room temperature. | LIP to use approved PowerPlans. These products are NOT bioequivalent, therefore, careful dosing and reassessment is needed if switching between products to prevent accidental overdose. Amphotericin B conventional dose should not exceed 1.5 mg/kg/day AmBisome, Amphotericin B Liposomal dose is between 3 – 5 mg/kg/day. | Pharmacists complete a verification double check on compounded products to verify correct dose and product. Compounding of lipid complex, the vial is gently agitated until all yellow sediment is dissolved. A 5micron filter is used with each vial injected. | Daily doses are infused over 2-6 hours. Must be administered using a programmable pump with the guardrail safety feature. May require pre-meds to decrease infusion related reactions. Flush lines before and after with D5W only. AmBisome, Amphotericin B Liposomal infusions: Do NOT use an inline filter. | Monitor for signs and symptoms of nephrotoxity. Monitor the patient's I&Os and SCr. Observe the patient for infusion related reactions which may include fever, chills, hypo or hypertension and tachycardia. Notify the prescriber of all side effects. |



High Alert – High Risk Medications 2020-2022

| Drug Class and Medication | Selection and Procurement | Storage | Ordering Verifying and Transcribing | Preparing or Compounding | Administration | Monitoring |
|------------------------------|--|--|---|---|--|---|
| Contrast Agents | | | | | | |
| IV Contrast Agents | Purchased by pharmacy in standard concentration, single dose containers. | Products are stored in pharmacy and dispensed upon request and stored in designated ADCs and locked storage cabinet in radiology and surgery. | See CPG.57 IV Contrast Guidelines Radiology technician to review patient's medications; compare them to medication reconciliation table; and take appropriate action as identified on medication reconciliation table. See Policy IS.03 Imaging Services Medication List | Only standardized concentrations, single dose containers shall be used. | For neonatal and pediatric patients, contrast agent IVP orders shall be given by either the physician or the NNP. Patients who have demonstrated past allergic reactions or who have a history of allergies will have the IV left in place throughout the procedure. Discard unused portion. | During the course of the exam, the patient shall be continually monitored by the appropriate healthcare practitioner for hives or difficulty breathing or any other changes. The patient shall not be left alone during the exam. |

VENTURA COUNTY HEALTH CARE AGENCY

High Alert – High Risk Medications 2020-2022

| Drug Class and Medication | Selection and Procurement | Storage | Ordering Verifying and Transcribing | Preparing or Compounding | Administration | Monitoring |
|------------------------------|---|---|--|---|---|---|
| Chemotherapy Agents, par | ental and oral | | | | | r |
| Chemotherapy Agents | Procured for separate use by both the Infusion Center Pharmacy and VCMC Main Pharmacy Department. | Stored per United States Pharmacopeia (USP) <800> requirements. See policy PH.27.02 Hazardous Drug Storage, Handling, Labeling, and Transport | Use approved pre- printed orders or PowerPlans when ordering chemotherapy. Patient's current height, weight and BSA must be used with each dose. | Only trained personnel to prepare chemo drugs in the appropriate Primary Engineering Control (PEC) per USP <797> and <800> guidelines. Pharmacy IDC of products, diluent and calculation before admixture occurs. Infusions to be pre- spiked and tubing primed prior to dispensing Closed system transfer devices used during preparation and administration Direct hand off to nurse 1:1 | Requires an IDC and documentation of order, calculation of final product, and review of pump settings with 2 licensed, competent HCP at the bedside and in the EHR. Personnel Protective Equipment (PPE) required. Use programmable pumps with guardrail safety feature. Consult Chemo Pharmacist if duration of infusion time needs to be adjusted. See policy 100.205 Safe Handling of Hazardous Medications | Verify labs prior to treatment. Documented regimen cycles to be completed. Monitor patient for adverse drug reactions. |



High Alert – High Risk Medications 2020-2022

| Drug Class and Medication | Selection and Procurement | Storage | Ordering Verifying and Transcribing | Preparing or Compounding | Administration | Monitoring |
|---------------------------------------|--|---|---|---|---|---|
| Electrolytes | | | | | | |
| calcium gluconate calcium chloride | Purchased by Pharmacy . Calcium Chloride is procured in prefilled syringes. Calcium Gluconate is procured in the vial form. | Calcium is stored in pharmacy, select boxes and kits, crash carts, and designated ADCs. Careful consideration to avoid LASA confusion whenever possible. | Specify the salt form of calcium. Order in milligram of calcium gluconate or calcium chloride. Do not order calcium in milligrams of elemental calcium. Do not order as "IM" or "SQ" routes of administration, always order as "IV." Use caution in patients who are on digoxin. | Diluted by the pharmacy 1:1 with normal saline for all calcium gluconate orders in NICU for a concentration of 50 mg/mL. Monitor for calcium – phosphate interactions in TPN solutions. | See Adult IV guidelines for restricted use. Administer by slow IV infusion using a programmable pump with guardrail safety feature. | Monitor any reports of burning sensation or tissue necrosis due to calcium administration. Monitor serum calcium and phosphate levels. |
| sodium chloride for injection | Purchased by pharmacy: 3% Hypertonic Saline pre-mixed NaCl 23.4% vials | Pre-mixed hypertonic saline and NaCl 23.4% are stored only in the pharmacy. | Hypertonic infusion orders must specify rate of infusion. Duration of therapy and frequency of sodium monitoring should be addressed | Only 3% Hypertonic Saline is available commercially. 2% Hypertonic Saline is compounded by pharmacy using 23.4% NaCl vials. | Requires an IDC and documentation with 2 nd licensed HCP at start of infusion. Must be administered using a programmable pump. 3% only via Central Line 2% preferred Central Line, but can be administered peripherally | Serum sodium levels monitored according to clinical indications – consult with prescriber or refer to the physician's order. |



| Drug Class and Medication | Selection and Procurement | Storage | Ordering Verifying and Transcribing | Preparing or Compounding | Administration | Monitoring |
|------------------------------|--|--|--|---|---|--|
| magnesium sulfate | Purchased by pharmacy in the 1 gm, 4 gm SDV and the 5gm and 10 gm multi-dose vials (MDV) Pre-mixed IV infusions of 2 gm/50 mL, 4 gm/100 mL, and 20 gm/500 mL are also purchased. | SDV and MDV are stored in pharmacy and restricted to compounding use. Exception: magnesium 1g/2 mL SDV available in crash carts and select ADCs Pre-mixed diluted magnesium IVPBs are available in select ADCs. | LIP to use approved PowerPlans. Magnesium must NOT be abbreviated to avoid LASA mix-up with morphine sulfate. Orders are standardized to order full grams of magnesium. | Standardized magnesium concentrations are premixed; 2 gm/50 mL, 4 gm/100 mL, and 20 gm/500 mL. | Infuse per Adult IV guidelines. Infusion of magnesium is required to be on a programmable pump with guardrail safety feature. | Monitor serum magnesium levels, watch for hypotension, hypocalcemia, hypophosphatemia and hyperkalemia. Monitor for impaired cardiac function. |
| potassium chloride (KCI) | Purchased by pharmacy Premixed IV infusions of 20meq/50mL for central line and 40meq/100mL are also purchased. | Pre-mixed (diluted) KCI is stored in the pharmacy and is available in ADCs. Concentrated K products are located in the pharmacy department and restricted to compounding use only. Careful consideration to avoid LASA confusion whenever possible | LIP to use approved PowerPlans. Do not order as bolus. Order only standardized K- rider doses and concentrations for both central line administration as well as peripheral line administration. See policy PH.83 Intravenous Potassium Administration for Adults | Standardized concentrations of pre-mixed and/or compounded products are dispensed. | Must be administered using a programmable pump with guardrail safety feature. Max rates, Do NOT exceed: 10 mEq/hr for non monitored beds Pediatrics 0.5 mEq/kg/hr –with 10 mEq/hr max 10 mEq/hr on ANY peripheral line Up to 40 mEq/hr on a central Line AND with a cardiac monitor | Monitor serum potassium levels with a CMP. Contact provider for orders exceeding a rate over 10 mEq/hr of KCI on Med/Surg floors. |



| Drug Class and Medication | Selection and Procurement | Storage | Ordering Verifying and Transcribing | Preparing or Compounding | Administration | Monitoring |
|---|---|---|---|---|---|---|
| potassium phosphate (KPhos) injection | Purchased by pharmacy | Concentrated KPhos vials are stored only in pharmacy and restricted to compounding only with careful consideration to avoid LASA confusion whenever possible. | LIP to use approved PowerPlans. Kphos should be ordered in mmol of phosphorous. | Standardized drip concentrations are compounded and dispensed. | 40 mEq = ~30mmol Recommended administration time for 30 mmol is over 6 hours. | IV phosphate replacement indicated for phos levels less than 1mg/dL, Monitor serum phosphate and calcium levels with a CMP. |
| Hypoglycemic Agents | | | | | | |
| Sulfonylurea Hypoglycemics (glyBURIDE, glipiZIDE) | Restricted in the inpatient setting: glyBURIDE – OB patients glipiZIDE – Patient's must NOT be NPO | Stored within the pharmacy with LASA precautions and in select ADCs | Pharmacists verifying the order will ensure restriction criteria are met prior to dispensing. | Available in unit dosed packaging. | Nursing to ensure bar code administration. Not to be given if patient is NPO. | Monitor for signs and symptoms of hypoglycemia especially in the elderly or those with ESRD. |



| Drug Class and Medication | Selection and Procurement | Storage | Ordering Verifying and Transcribing | Preparing or Compounding | Administration | Monitoring |
|--------------------------------|--|--|--|---|--|--|
| Insulin subcutaneous and IV | Purchased by pharmacy To encourage safe use of insulin and to help reduce LASA issues with the injectable insulins, VCMC and SPH has approved restricted inventory of products: Ultra short-acting insulin: Lispro Long-acting insulin: Lantus Intermediate insulin: NPH Short-acting: Regular insulin is restricted for use in insulin infusions, hyperkalemia, and for hyperglycemia in ED only. Not for use in pediatric DKA. | Stored in ADCs as a MDV vial for initial doses but treated as a SDV. All MDV vials will be labeled with a 28 day expiration date and patient information when dispensed from the pharmacy for one specific patient use. In the main pharmacy, regular insulin is stored separately from other insulin formulations. | LIP to use approved PowerPlans for both subcutaneous and infusion orders. This also includes hypoglycemia treatment orders. Do not use the abbreviation "U" when ordering insulin, units must be spelled out. Do not place slash when ordering NPH and regular insulin. | Use only U-100 insulin. Do not draw insulin in TB syringes. Do not give NPH as an IV. All IV Insulin infusions of REGULAR insulin are compounded in a single standard concentration for adults (1 unit/ mL). | Requires an IDC and documentation with second, licensed HCP on the dose being administered (IV and SQ) as well as initial infusion, dose adjustments, and bolus doses for IV route of administration. Must use programmable pump for insulin infusions. GlucoStabilizer software is mandatory for all insulin infusions requiring nurse titrations in adult patients. | Monitor patients' BG according to physician's order. Monitor use of Dextrose 50% and patients with blood glucose levels < 70 mg/dl. Monitor inappropriate use of "U" instead of "units" in orders for insulin Note: For IV Insulin infusions monitor patient's BG per GlucoStabilizer |



High Alert – High Risk Medications 2020-2022

| Drug Class and Medication | Selection and Procurement | Storage | Ordering Verifying and Transcribing | Preparing or Compounding | Administration | Monitoring |
|--|--|---|---|---|---|---|
| Moderate Sedation Agents, I | V (e.g. dexmedetomidine | e, midazolam, LORazep | am) | | | |
| Moderate Sedation Agents | Purchased by pharmacy in SDV, MDV and in pre-mixed solutions when available. | Stored in ADCs in locked lidded pockets. Whenever possible, SDV will not be loaded into ADCs in areas that only require minimal sedation (anxiolysis) Instead oral options will be made available. | LIP to use approved PowerPlans to order infusions. Physician orders includetitration parameters and hold parameters. | Infusions not available in the premixed concentrations will be compounded by the Pharmacy Department. | All titratable drips require the use of the pump with the safety guardrail. IV Pushmedications per IV administration guidelines Requires an IDC without MAR documentation for start of infusion and bag changes. | For titratable drips, monitoring parameters must be ordered and documented on the EHR (interactive view) with nurse driven titrations as outlined in the titratable drips policy CC.23 Intravenous Medication Titration in Critical Care Areas See policy 100.070 Moderate and Deep Sedation |
| Neuromuscular Blocking Age | ents (NMBA) | | | | | |
| Neuromuscular Blocking Agents (NMBA) | Purchased by pharmacy <u>Cisatracurium</u> 20 mg/10 mL MDV <u>Rocuronium</u> 50 mg/5 mL MDV <u>Succinylcholine</u> 100 mg/5 mL PFS 200mg/10 mL MDV Vecuronium 10mg SDV | Segregated or stored in high alert bins in pharmacy. Stored in special locked intubation kits, in designated ADCs, in locked-lidded pockets, and in OR trays. Refrigerated rocuronium has a 60 day BUD out of the fridge. Succinylcholine PFS has a 90 day BUD. | LIP to ensure adequate pain and sedation control prior to and during the use of NMBA drips for patients in the critical care areas. Do not refer to neuromuscular blockers as "relaxants". | Pharmacy completes a verification double check of standardized drip concentrations comp ounded by pharmacy. See Adult IV guidelines. Pharmacy to dispense vials, drips, and PFS with auxillary labels whenever possible to designate that these medications are paralyzing agents. | Stipulate neuromuscular blockers are to be discontinued and paralysis status checked (e.g. train of four = 4/4) when patient is extubated and removed from the ventilator. Use a programmable pump for NMBA IV infusions. | Check reflexes. Motor/sensory responses. Use Train-of-four for monitoring NMBA effectiveness. Ensure adequate pain and sedation has been achieved prior to initiation and during NMBA drip use. |



High Alert – High Risk Medications 2020-2022

| Drug Class and Medication | Selection and Procurement | Storage | Ordering Verifying and Transcribing | Preparing or Compounding | Administration | Monitoring |
|------------------------------|------------------------------|---|---|--|--|---|
| Opioids, oral, IV, and tra | ansdermal | | | | | |
| Opioids | Purchased by pharmacy | Products are stored in secure locked storage areas and ADCs in locked lidded pockets with careful consideration to avoid LASA confusion whenever possible. The lowest strength presentation of opiate injectables will be loaded into the ADC whenever possible. Fentanyl patches are not loaded in areas that treat primarily acute pain whenever possible. | LIP to use approved PowerPlans or subphases for all patient controlled analgesia (PCA), titratable, and palliative care orders. The abbreviation "MS" is not accepted for morphine. Use lower recommended starting doses in opiate naïve patients. Use caution with concurrent benzodiazepines due to respiratory depression and possible death. LIPs are not to order fentanyl patches for opioid naïve patients or patients with acute pain (see fentanyl patch policy for exception) | Standard concentrations are purchased or compounded by pharmacy. | PCAs require an IDC and documentation by 2 licensed HCP for all PCA settings including initial dose, rate changes and syringe changes. For infusions, titrate per prescribers ordered parameters (see titratable drips) Lockboxes and portless tubing should be used for all end-of-life controlled substance infusions and at the care team's discretion. For fentanyl patches, see policy PH.118 | For pain assessment, management, and documentation, see policy 100.076 Refer to policy 100.230 Naloxone is available in all ADCs and crash carts as a reversal agent. |



High Alert – High Risk Medications 2020-2022

| Drug Class and Medication | Selection and Procurement | Storage | Ordering Verifying and Transcribing | Preparing or Compounding | Administration | Monitoring |
|---|--|--|--|---|---|--|
| Parenteral Nutrition Solution | s | | | | | |
| Parenteral Nutrition (PN) Solutions | Procurement outsourced to CAPS for VCMC only. Base solution and ingredients purchased by the Pharmacy Department with careful consideration to avoid LASA confusion whenever possible. | CAPS delivery by 1800 and pharmacy will deliver PN to the floors for imminent administration. Ingredients stored in pharmacy with concentrated electrolyte sections. | NICU and PEDs PN orders are computer generated, signed by the LIP and faxed to the Pharmacy by 1100 daily. All other PNs are ordered using approved PowerPlans and are delivered to pharmacy by 1200 for processing daily. | PN to be outsourced to CAPs for VCMC only. Pharmacists complete a verification double check before dispensing. If a PN is compounded, pharmacist performs a manual check of all additives prior to injection into final product including a visual inspection of the final product. | Requires a verification double check and documentation at start of infusion and with bag changes. All PNs require a 0.2 micron filter. Replace all PN's daily at 1800. | Monitor blood glucose for hypo or hyperglycemia. Monitor electrolytes and nutritional requirements daily. |
| Titratable Drips | | | | | | |
| Titratable Drips for Adults | Purchased by Pharmacy in premixed solutions and in standardized concentrations whenever possible. | Stored in the pharmacy and in designated ADCs | LIP to order using approved PowerPlans. Order includes titration parameters and hold order information. Pharmacist may assist in order entry of standardized double and quadruple strength concentrations using approved PowerPlans | Drips not available in the premixed concentrations will be compounded by the Pharmacy Department and require a verification double check before dispensing. Drips to be labeled with colored drip identifiers to help reduce LASA mix- ups prior to dispensing. | All titratable drips require the use of the pump with the safety guardrail requires an IDC without documentation for start of infusion and bag changes | Monitoring parameters must be documented as outlined in the Adult titratable drip guideline (see policy CC.23) |

HEALTH CARE AGENCY

High Alert – High Risk Medications 2020-2022

| Drug Class and Medication | Selection and Procurement | Storage | Ordering Verifying and Transcribing | Preparing or Compounding | Administration | Monitoring |
|------------------------------|--|---|---|--|--|--|
| Vasopressors | | | | | | |
| Vasopressors | Purchased by pharmacy in standard concentrations of SDV, ampules, and PFS | Stored in pharmacy and in designated ADCs, epidural cart, and in crash carts. LASA strategies employed: TALL man lettering, color and shape variability, reverse print, and physical storage separation. | LIP to order using approved PowerPlans and/or for specific dose. | Drips are compounded by pharmacy in standard concentrations (see titratable drips). Standard concentration of single dose ampules and vials and PFS shall be obtained from designated crash carts and ADCs. | See adult IV administration guidelines | Monitoring parameters must be documented as outlined in the Adult titratable drip guideline (see policy CC.23) |
| EPINEPHrine | EPINEPHrine 1 mg/mL 1 mL ampule 30mL SDV EPINEPHrine 0.1 mg/mL abboject emergency syringe EPINEPHrine 10 mcg/mL PFS **PRESSOR DOSE** | EPINEPHrine 10 mcg/mL PFS **PRESSOR DOSE **: restricted to the following ADCs: ICU3, SP ICU, ED, SP ED, PACU, SP PACU, OR, SP OR. | EPINEPHrine 10 mcg/mL PFS **PRESSOR DOSE ** restricted to acute hypotension in patients with cardiac dysfunction ONLY. NOT for ACLS. | | **PRESSOR DOSE** PFS is a rapid IVP through central venous access (preferred). In an emergent setting peripheral venous/ intraosseous (IO) access is allowed. **PRESSOR DOSE** requires an IDC without documentation with a second licensed HCP. | **PRESSOR DOSE** PFS requires continuous HR and BP monitoring, preferably through an arterial catheter. |
| PHENYLephrine | PHENYLephrine 10 mg/mL SDV 1mL 5mL PHENYLephrine 100 mcg/mL_PFS **PRESSOR DOSE** | PHENYLephrine 100 mcg/mL PFS **PRESSOR DOSE** is restricted to the following ADCs: ICU3, SP ICU, ED,SP ED, PACU, SP PACU, OR, and SP OR. | PHENYLephrine 100 mcg/mL PFS **PRESSOR DOSE** is restricted to acute hypotension ONLY. | | | |

Approved: 2/2020 P&T and MEC